Therapeutic Area

JAK Inhibitor

Therapeutic area intelligence for JAK Inhibitor with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 4

Companies

Concord Biotech →

Incyte Corporation →

Orient Pharma →

Saptalis Pharmaceuticals →

Assets

Recent signals(6)

RegulatoryJune 21, 2026

FDA Accepts ANDA for Tofacitinib Citrate by YAOPHARMA

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tofacitinib Citrate submitted by YAOPHARMA.

StrategyJune 21, 2026

FDA Grants Approval for Tofacitinib Citrate ANDA219830 by Orient Pharma

The FDA has granted approval for the ANDA219830 application for Tofacitinib Citrate submitted by Orient Pharma.

StrategyJune 21, 2026

FDA Approves ANDA for Tofacitinib Citrate by Auson

The FDA has approved the ANDA219370 for Tofacitinib Citrate submitted by Auson.

StrategyJune 21, 2026

FDA Grants Approval for Tofacitinib Citrate ANDA218821 by Concord Biotech

The FDA has granted approval for ANDA218821, a generic version of tofacitinib citrate submitted by Concord Biotech.

StrategyJune 21, 2026

FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals

The FDA has granted approval for ANDA218900, a generic version of Tofacitinib Citrate, submitted by Saptalis Pharmaceuticals.

CompetitiveJune 18, 2026

Apotex Inc. Submits ANDA for Ruxolitinib

Apotex Inc. has submitted an Abbreviated New Drug Application (ANDA) for Ruxolitinib, indicating a move to enter the market.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.